SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis

Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020;41(5):733–55.

PubMed Central  Article  Google Scholar 

Mobasseri M, Shirmohammadi M, Amiri T, Vahed N, Hosseini Fard H, Ghojazadeh M. Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis. Health Promotion Perspectives. 2020;10(2):98–115.

PubMed  PubMed Central  Article  Google Scholar 

Harjutsalo V, Thomas MC, Forsblom C, Groop PH. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. Diabetes Obes Metab. 2018;20(12):2759–67.

CAS  PubMed  Article  Google Scholar 

Hägg S, Thorn LM, Putaala J, Liebkind R, Harjutsalo V, Forsblom CM, et al. Incidence of stroke according to presence of diabetic nephropathy and severe diabetic retinopathy in patients with type 1 diabetes. Diabetes Care. 2013;36(12):4140–6.

PubMed  PubMed Central  Article  Google Scholar 

Toschi E, Bailey RJ, Miller KM, Calhoun PM. Improvement in A1c levels in early adulthood in the T1D exchange: impact of racial, socioeconomic, and clinical factors. J Clin Endocrinol Metab. 2021;106(5):1294–302.

PubMed  Article  Google Scholar 

Foster NC, Beck RW, Miller KM, Clements MA, Rickels MR, DiMeglio LA, et al. State of Type 1 diabetes management and outcomes from the T1D exchange in 2016–2018. Diabetes Technol Ther. 2019;21(2):66–72.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Leoncini G, Viazzi F, De Cosmo S, Russo G, Fioretto P, Pontremoli R. Blood pressure reduction and RAAS inhibition in diabetic kidney disease: therapeutic potentials and limitations. J Nephrol. 2020;33(5):949–63.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Helve J, Sund R, Arffman M, Harjutsalo V, Groop P-H, Grönhagen-Riska C, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. Diabetes Care. 2018;41(3):434–9.

PubMed  Article  Google Scholar 

Kristófi R, Bodegard J, Norhammar A, Thuresson M, Nathanson D, Nyström T, et al. Cardiovascular and renal disease burden in type 1 compared with type 2 diabetes: A Two-Country nationwide observational study. Diabetes Care. 2021;44(5):1211–8.

PubMed  PubMed Central  Article  CAS  Google Scholar 

Costacou T, Orchard TJ. Cumulative kidney complication risk by 50 years of Type 1 diabetes: the effects of sex, age, and calendar year at onset. Diabetes Care. 2018;41(3):426–33.

PubMed  Article  Google Scholar 

Groop PH, Thomas MC, Moran JL, Wadèn J, Thorn LM, Mäkinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009;58(7):1651–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Harjutsalo V, Forsblom C, Groop PH. Time trends in mortality in patients with type 1 diabetes: nationwide population based cohort study. BMJ. 2011;343:d5364.

PubMed  PubMed Central  Article  Google Scholar 

Groop PH, Thomas M, Feodoroff M, Forsblom C, Harjutsalo V. Excess mortality in patients with type 1 diabetes without albuminuria-separating the contribution of early and late risks. Diabetes Care. 2018;41(4):748–54.

PubMed  Article  Google Scholar 

Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134(10):752–72.

CAS  PubMed  Article  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.

CAS  PubMed  Article  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24.

CAS  PubMed  Article  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease.  N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.

Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638–42.

CAS  PubMed  Article  Google Scholar 

Wolfsdorf JI, Ratner RE. SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care. 2019;42(6):991–3.

CAS  PubMed  Article  Google Scholar 

Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, et al. Exploring patient preferences for adjunct-to-insulin therapy in type 1 diabetes. Diabetes Care. 2019;42(9):1716–23.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Verma S, McMurray JJV, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: The search for the sweet spot in heart failure. JAMA Cardiol. 2017;2(9):939–40.

PubMed  Article  Google Scholar 

Thomas MC, Cherney DZI. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia. 2018;61(10):2098–107.

CAS  PubMed  Article  Google Scholar 

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, et al. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018;93(1):231–44.

CAS  PubMed  Article  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.

CAS  PubMed  Article  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.

CAS  PubMed  Article  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.

CAS  PubMed  Article  Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.

CAS  PubMed  Article  Google Scholar 

Cherney DZI, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley R, et al. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021;64(6):1256–67.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.

CAS  PubMed  Article  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.

CAS  PubMed  Article  Google Scholar 

Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.

CAS  PubMed  Article  Google Scholar 

Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. Diabetes Obes Metab. 2019;21(10):2192–202.

CAS  PubMed  Article  Google Scholar 

Garg SK, Peters AL, Buse JB, Danne T. Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: A STICH protocol. Diabetes Technol Ther. 2018;20(9):571–5.

PubMed  Article  Google Scholar 

• Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019;42(6):1147–54. This Consensus Report written by an international team of physicians and researchers with expertise in using SGLT2 inhibitor therapy. The report summarizes and reviews the current research regarding SGLT2 inhibitor use in addition to providing recommendations and strategies to enhance the safety (mitigating risk of DKA in particular) of SGLT2 inhibitors in individuals with type 1 diabetes.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lam CSP, Karasik A, Melzer-Cohen C, Cavender MA, Kohsaka S, Norhammar A, et al. Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study. Diabetes Obes Metab. 2021;20(6):1431–5.

Article  CAS  Google Scholar 

Koh ES, Han K, Nam YS, Wittbrodt ET, Fenici P, Kosiborod MN, et al. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Diabetes Obes Metab. 2021;23(2):455–66.

CAS  PubMed  Article  Google Scholar 

Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jorgensen ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol. 2020;8(7):606–15.

CAS  PubMed  Article  Google Scholar 

留言 (0)

沒有登入
gif